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INTRODUCTION 
over the past thirty years, numerous studies have 
attempted to determine whether Type A behavior (TAB) is a 
risk factor for coronary heart disease (CHO; see Booth-
Kewley & Friedman, 1987). TAB has been defined as a pattern 
of behaviors including "extremes of competitive achievement 
striving, hostility, aggressiveness, and a sense of time 
urgency, evidenced by vigorous voice and psychomotor 
mannerisms" (Matthews, 1988). Type B's are individuals who 
do not display the characteristics of Type A's. 
Contradictory findings in research on TAB and CHO have 
spurred so much debate that Dimsdale (1988) has suggested 
the 'A' in TAB might well stand for acrimony. The purpose 
of this dissertation is to identify the study 
characteristics associated with positive and null findings. 
At the heart of the debate over inconsistent findings 
in research on TAB and CHD is the failure of recent studies 
to replicate the findings of previous research. Before 
1978, the findings from a number of studies converged in 
suggesting that TAB is a risk factor for CHD. In fact, the 
evidence in 1978 was sufficiently convincing that a review 
panel from the National Heart, Lung and Blood Institute 
(NHLBI) concluded that TAB is a risk factor for CHD of equal 
magnitude to the traditional risk factors (smoking, serum 
cholesterol, and blood pressure). 
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Suddenly after the NHLBI panel's findings were 
published, Type A's no longer seemed to be at greater risk 
for CHO. In contrast to the consistent and strong 
relationship reported prior to 1978, a remarkable number of 
subsequent studies failed to find an association between TAB 
and CHO (for reviews, see Booth-Kewley, 1987; Matthews, 
1988). The trend towards null findings has been so 
consistent that the participants of the 1987 annual meeting 
of the Psychosomatic Society questioned the relevance of the 
whole Type A concept (Staff, 1987). 
Perhaps the most disconcerting evidence has been the 
results of Ragland and Brand's (1988a,b) twenty-two year 
follow-up study; this study was based on subjects who 
participated in the first prospective study to report an 
association between TAB and CHO. Ragland and Brand (1988a) 
reported that Type B's with prior CHO incurred a second 
fatal myocardial infarction (MI) in less time than Type A's. 
Furthermore, healthy Type A's were no more likely than Type 
B's to incur a fatal MI (Ragland & Brand, 1988b). To the 
chagrin of many researchers (Correspondence, 1988), these 
results were interpreted by some as suggesting that TAB is 
not a risk factor for CHO. 
However, not all of the recent research has 
contradicted earlier findings. One true experimental study 
successfully reduced the number of subsequent episodes of 
CHO in a treatment condition that was designed to modify TAB 
2 
(Friedman et al., 1986). These results suggest TAB produces 
CHO. 
The research discussed in the current dissertation 
attempts to identify some of the reasons for the confusing 
results in research on TAB and CHO by a quantitative review 
of the literature. The first chapter introduces a Decision 
Theory (OT) model that can be used to define subject 
selection biases that may have occurred in research on TAB 
and CHO. The OT model is used to develop hypotheses 
concerned with how subject selection biases can influence 
the results of a study. The second chapter discusses the 
methods used in the quantitative review and a third chapter 
discusses the results. The results lend support to the 
value of the OT model by suggesting that a type of subject 
selection bias referred to as diseased based spectrum (DBS) 
bias has produced some of the null findings in recent 
studies. The fourth chapter discusses the implications of 
the results for future research on TAB and CHO. The final 
chapter discusses general implications of the OT model for 
future research. This chapter illustrates how another 
subject selection bias (mortality bias) can be described by 
the OT model. In addition, a formula is presented for 
estimating the reduction in correlation between TAB and CHO 
in a study that is vulnerable to DBS bias. 
3 
A DECISION THEORY (OT) MODEL OF SUBJECT SELECTION BIASES 
study Designs Used in Research on TAB and CHD 
Before discussing the DT model, the following section 
reviews the different types of study designs used in 
research on TAB and CHD. A major purpose of the research 
described in this dissertation is to determine how subject 
selection biases influence the magnitude of the relationship 
between TAB and CHD. study design determines subject 
selection procedures. Therefore, clear and explicit 
categories of study design based on the method of subject 
selection are necessary for assessing the influence of 
subject selection on the results of research on TAB and CHD. 
The most frequently used study designs in research on 
TAB and CHD have included (a) recurrent CHD studies, (b) 
angiography studies, (c) studies that select patients on the 
basis of their risk factor status, (d) population studies, 
(e) case-control studies and (f) healthy population 
prospective studies. These study designs have been referred 
to as epidemiological study designs because these types of 
study designs have frequently been employed in 
epidemiological research. These study designs vary in how 
subjects are selected by whether the design is (a) high risk 
or healthy population, (b) cross-sectional or prospective 
designs and (c) the method used to recruit subjects. 
For the current paper, the phrase "high risk" study 
design refers to a study design in which only subjects with 
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at least some disease are selected for study. Therefore, 
only a part of the full range of disease severity is 
examined in high risk studies1 • In contrast, "healthy 
population" studies sample subjects across the full spectrum 
of disease. In particular, study designs are considered to 
be "high risk" if a comparison group includes individuals 
with substantial disease. These comparison groups with 
substantial disease are referred to as high risk comparison 
groups. Alternatively, comparison groups that include 
individuals who are healthy are referred to as healthy 
comparison groups. Studies that use healthy comparison 
groups are referred to as healthy population studies. 
Research on TAB and CHO has used three types of high 
risk study designs: (a) angiography studies, (b) recurrent 
CHO studies and (c) studies that select subjects on the 
basis of their risk factor status. Healthy population 
studies include the following study designs: (a) healthy 
population prospective studies, (b) case-control studies and 
(c) cross-sectional population studies. 
In recurrent CHO studies, subjects are selected who 
have incurred a MI; these subjects are followed over time to 
determine which subjects develop recurrent CHO. Individuals 
with a previous MI who do not develop future CHO (a high 
risk comparison group) are compared with individuals who 
develop recurrent CHO in the future (a diseased group). 
Researchers have expected that a higher percentage of 
5 
individuals with recurrent CHO should be Type A than 
individuals who do not experience recurrent CHO. Recurrent 
CHD studies constitute a high risk study design. 
A second type of high risk study is an angiography 
study. An angiography is a diagnostic test that is used to 
determine the extent of a patient's coronary artery disease 
(CAD); CAD is a precursor to most cases of MI. In research 
on TAB, individuals who are diagnosed by the results of an 
angiography as having clinically relevant CAD are compared 
with subjects who are diagnosed as having less CAD. 
Researchers have expected that a higher proportion of the 
diseased group would be Type A than the high risk comparison 
group. 
An angiography study is a type of "high risk" study 
because the comparison group includes many individuals with 
CAD. Diagnostic screening procedures (e.g., stress testing) 
insure that most patients undergoing diagnostic coronary 
angiography have substantially more CAD than healthy 
individuals. Therefore, almost all subjects who undergo 
angiography have substantial CAD. This fact may account for 
why researchers have found only minimal differences in the 
degree of disease severity found in comparison and diseased 
groups in angiography studies (Fried & Pearson, 1987). 
Some studies selected subjects on the basis of their 
risk factor status; these studies only select subjects who 
are considered to be at high risk for future CHD. The 
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subjects in these studies are at high risk for future CHO 
because they possess some known risk factor (e.g., serum 
cholesterol) for CHO. The comparison groups in these 
studies frequently include subjects with subclinical disease 
produced by the presence of traditional risk factors. Thus, 
a study that selects subjects on the basis of their risk 
factor status is a type of high risk study. 
There are two types of healthy population studies: (a) 
population studies and (b) case control studies. In 
population studies, subjects are sampled from community 
populations (e.g., towns or a factory). For healthy 
population studies, subjects without CHO are compared with 
subjects with CHO who live in the same population. In case 
control studies, individuals with CHO are selected from 
hospital(s) or physician(s) practices. Healthy individuals 
are selected from the same population as the individuals 
with CHO. For example, some case control studies have used 
patients in the same hospital without CHO as control 
subjects. 
In prospective studies, subjects are selected on the 
basis of their disease status, and they are followed over 
time to determine which alleged risk factors predict future 
disease. In cross-sectional studies, individuals are 
assessed at a single point in time. 
Recurrent CHO and healthy population prospective 
studies are specific types of prospective studies. For 
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healthy population prospective studies, only healthy 
individuals are initially selected for study. Population 
studies, case-control studies and angiography studies are 
types of cross-sectional studies. Studies that select 
subjects on the basis of their risk factor status may be 
cross-sectional or prospective. 
Studies have recruited subjects with CHD by four 
methods: (a) selection on the basis of risk factor status, 
(b) selection by the results of an angiography in which 
subjects were diagnosed as having clinically significant 
CAD, (c) selection because the individual developed CHD 
during the course of a prospective study and (d) selection 
because the subject worked in a company or town 
participating in a study. Studies have either recruited 
healthy subjects from (a) specific populations (e.g, towns, 
communities, patients in hospitals without CHD disease) or 
(b) used volunteers. 
A Decision Theory CDT) Model for Describing Subject 
Selection Biases 
The need for a statistical model. All of the different 
types of study designs used in research on TAB and CHD are 
vulnerable to subject selection biases. However, not all 
designs are vulnerable to the same biases. The degree to 
which the various subject selection biases influence 
research on TAB and CHD is unknown. Thus, the magnitude of 
the association between TAB and CHD found in any given study 
8 
may be biased by subject selection biases (Matthews, 1988). 
Therefore, there is a great deal of confusion regarding the 
interpretation of results in research on TAB and CHO 
(Dimsdale, 1988). 
Researchers can test hypotheses concerning how subject 
selection biases by examining how the magnitude of the 
association between TAB and CHO varies across different 
study designs. Thus, determining the extent to which 
subject selection biases have contributed to different 
findings in research on TAB and CHO has implications for the 
types of study designs that are employed in future research 
and how the results of research on TAB and CHD is 
interpreted. 
The study designs used in research on TAB and CHD are 
vulnerable to two types of subject selection biases: (a) 
spectrum and (b) selection biases. Research suggests 
spectrum and selection biases have led to a number of 
confusing and contradictory findings in epidemiological 
research (Ransohoff & Feinstein, 1978). 
Given that biases are an important problem in 
epidemiological research, a general strategy for defining 
and testing for such biases would be useful. The 
differences between spectrum and selection bias become 
clearer when a statistical model is used to define these 
biases. Decision Theory (DT) is a statistical model that 
can be used to define spectrum and selection biases (Miller 
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et al., 1988). The following paragraphs describe the OT 
model introduced in Miller et al. This OT model is then 
used to develop hypotheses to detect the presence of 
spectrum and selection biases in research on TAB and CHO. 
In addition, the OT model can be used to develop hypotheses 
regarding which biases influence each type of study design. 
The OT model. Figure l(a) illustrates the results of a 
hypothetical healthy population study of the relationship 
between TAB and CHO in terms of the OT model. The x-axis 
represents a continuum of the degree of CHO in the sample. 
Higher values indicate greater severity of CHO. Negative 
values on the x-axis represent the healthy range and 
positive values represent the diseased range. The y-axis 
indicates the frequency of individuals at each level across 
the full spectrum of CHO. 
The cutpoint labeled Q in Figure l(a) is used to 
distinguish healthy individuals from individuals with CHO. 
The Q indicates the point at which CHO is sufficiently 
severe that some evidence of CHO (i.e., MI or angina) is 
present. Of course, no exact point exists at which CHO is 
universally expressed. The Q value only represents a mean 
value. 
One of the two frequency distributions illustrated in 
Figure l(a) represents all Type A's in the hypothetical 
study sample and the other distribution represents all Type 
B's. The OT model illustrated in Figure 1 assumes Type A's 
10 
Figure 1 
A Decision Theory Model of DBS and Mortality Bias 
(a) A Healthy Population 
Study 
-3 -2 -1 0 
healthy subjec .s 
Type A's 
(bl DBS bias in a Recurre~ .. : .••. 
CHD Study nt ~ · . · 
(c) Mortality bias 
Subjects excluded 
from the study 
Type A'!= 
-3 -2 -1 0 
healthy s bjects 
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d' 
Type B's 
2 3 
diseased 
subjects 
c c' 
Recurrent 
CHD 
Type B's 
2 3 
Subjects excluded 
by mortality bias 
develop CHD more frequently than Type B's. Thus, the 
frequency distribution associated with more CHD represents 
individuals who are Type A's and the distribution associated 
with less CHD represents individuals who are Type B's2 • The 
frequency distribution of Type A's is the same magnitude as 
the Type B distribution because prior research suggests that 
healthy populations include equal numbers of Type A's and 
B's (see Miller et al., 1988). 
Assessment of statistical association. The effect size 
(g') illustrated in Figure l(a) is an indicator of the 
degree of statistical association and represents the 
standardized mean difference in degree of disease between 
the two distributions of individuals with and without the 
risk factor (Glass, Smith & McGraw, 1981). In Figure l(a), 
g' represents the standardized mean difference in degree of 
CHD between the Type A's and Type B's. However, this method 
of assessing statistical association in research on TAB and 
CHD has not been used. Instead, researchers have analyzed 
their results by contingency tables. 
A contingency table can be used to describe the degree 
of statistical association between TAB and CHD in the 
hypothetical study sample illustrated in Figure l(a). The 
frequency distributions can be arranged into the four groups 
in the contingency table presented in Table 1. In this 
table, Type B's with CHD are referred to as false negatives 
(FN) because CHD is not expected to be present. Healthy 
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Table 1 
A,_Contingency Table of Disease versus Risk Factor Status 
Disease Status 
Coq:>arison Group Diseased Group 
False True 
Risk Type A's Positives CFP) Positives (TP) 
factor 
status 
Type B's True False 
Negatives CTN) Negatives (FN) 
Relative Risk (RR) = CTP)(TN + FN)/(FP + TP)(FN) 
Odds ratio = (TP)(TN)/(FP)(FN) 
TP 
Sensitivity = ----------
CTP + FN) 
TN 
Specificity = -----------
(FP + TN) 
13 
Type A's are ref erred to as false positives (FP) . Type A's 
with CHO are ref erred to as true positives (TP) and healthy 
Type B's are ref erred to as true negatives (TN). 
Two indices--the sensitivity and the specif icity--have 
been used to describe the relation between TAB and CHO. The 
sensitivity indicates the degree to which TAB can identify 
individuals with CHO in the diseased group. For example, 
69% of the subjects who developed CHO were Type A's in the 
Western Collaborative Group Study (WCGS; Rosenman, Brand, 
Jenkins, Friedman, Straus, & Wurm, 1975). The WCGS was the 
first prospective study that examined the relationship 
between TAB and CHO. Therefore, the sensitivity in the WCGS 
study is 69%. 
The specificity is estimated with data from the 
comparison group. The percentage of healthy subjects who do 
not possess the risk factor (i.e., Type B's) in the 
subsample is referred to as the specificity. The 
specificity indicates the degree to which the absence of the 
risk factor is associated with the absence of the disease. 
For example, the specificity of TAB was 52% in the WCGS 
because 52% of the individuals who remained healthy in that 
study were Type B's. High values of sensitivity and 
specificity indicate there is a strong association between 
the risk factor and the disease. 
Two indices have been used in research on CHO to 
indicate the degree of statistical association present in 
14 
Table 1. The relative risk (RR) is an index that indicates 
the increased risk for CHO associated with the pre$ence of 
TAB in a prospec.ti ve study. In research on TAB and CHO, the 
RR represents the increased odds of Type A's developing CHO 
compared with Type B's. A slightly different statistic--the 
odds ratio--is used for cross-sectional studies. The 
formulas for these two types of risk ratios are presented at 
the bottom of Table 1. Risk ratio indices indicate rate of 
change just as the slope in a regression equation indicates 
rate of change. 
The chi-squared test is used to determine whether the 
association between TAB and CHO in the contingency table is 
statistically significant. The magnitude of the chi-squared 
statistic is influenced by both the sensitivity and the 
specificity. That is, larger values of the chi-squared 
statistic are associated with higher risk ratios. 
Disease Based Spectrum COBS) Bias in High Risk Studies 
Spectrum bias is synonymous with range restriction. 
That is, spectrum bias is present when the variability on 
one variable is restricted so that the correlation between 
the variable with other variables is different than it would 
be if the entire range of values on the variable were 
examined. DBS bias occurs when disease status is used to 
select subjects for study independently of their risk factor 
status (Miller et al., 1988). When subjects are selected in 
this manner, the range of disease in the sample is 
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restricted. For example, the level of disease severity may 
not vary greatly between the high risk comparison group and 
diseased group if only individuals with severe disease are 
selected for study. This narrow spectrum of disease in the 
study sample may decrease any existing differences between 
the percentage of Type A's found in a high risk comparison 
group and a diseased group. 
DBS bias may occur frequently in high risk studies. 
For example, Miller, Turner, Tindale and Posavac (1988) 
found evidence to suggest that the narrow spectrum of 
disease severity in angiography studies reduces correlations 
between TAB and CAD. Therefore, researchers may find no 
relation between TAB and CHD in high risk studies and 
falsely conclude that there is no relation between TAB and 
CHD. 
Figure l(b) can be used to describe DBS bias in terms 
of the DT model and to illustrate how DBS bias reduces 
statistical associations in high risk studies. For example, 
Figure l(b) could represent the relation between TAB and CHO 
in a recurrent CHD study. The point labeled £' in Figure 
l(b) represents the point at which individuals who have 
already incurred a MI develop sufficient CHD to incur 
recurrent CHD (angina or a second MI). A comparison of 
Figure l(a) and (b) can be used to illustrate the difference 
between healthy population and recurrent CHD studies. 
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The spectrum of CHO in the high risk comparison group 
is attenuated in Figure l(b). That is, the range of values 
on the x-axis is decreased in the recurrent CHO study. 
similarly, other types of high risk studies exclude most 
healthy individuals from the study. Therefore, Figure l(b) 
illustrates a situation that occurs in all types of high 
risk studies. 
For the healthy population studies described in Figure 
l(a), more Type B's than Type A's are present in the healthy 
range of individuals. Recall that the healthy and diseased 
range of individuals is defined by the Q. Thus, the 
individuals with low negative scores on the x-axis represent 
healthy individuals included in healthy population 
comparison groups. 
Only individuals between Q and Q' are included in the 
high risk comparison groups used in recurrent CHO studies. 
For high risk studies, the specificity is estimated as the 
percentage of the sample located between Q and Q' that is 
Type B. More Type A's than B's are included in this range 
of the continuum of CHO. Subjects from the healthy end of 
the CHO continuum--where more Type B's are present--are 
excluded from recurrent CHO studies. Therefore, the 
specificity found in high risk studies is generally much 
lower than the specificity found in healthy population 
studies (Miller et al., 1988). The high percentage of Type 
A's found among those subjects in the high risk comparison 
17 
group lowers the specificity and the value of the chi-
squared statistic. Therefore, high risk studies may find 
only a small association between TAB and CHO even when a 
strong relationship exists in the entire population. 
An example may help to illustrate the degree to which 
DBS bias can attenuate statistical associations in high risk 
studies. Table 2 illustrates the healthy population and 
recurrent CHO study findings of the WCGS. For the healthy 
population results, the specificity (49%) is adequate and 
the study reported a statistically significant chi-squared 
statistic between TAB and CHO and the RR was 2.5. The 
specificity in the recurrent CHO study is much lower (30%), 
the relation between TAB and recurrent CHO is not 
statistically significant, and the RR is smaller (RR= 1.1). 
Selection Biases 
Selection bias is defined as occurring when the 
"subjects' status on a hypothesized risk factor and the 
disease jointly determine which subjects are selected into 
the study" (Miller et al., 1988). That is, some third 
variable that is correlated with both the risk factor and 
the disease is used to select subjects. 
For the current paper, one type of selection bias is 
used to illustrate how the OT model can be used to describe 
selection biases. This selection bias is referred to as age 
bias. Age bias is defined as occurring in research on TAB 
and CHO when TAB and CHO status jointly determine which 
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Table 2 
Description of the WCGS at the 4.5 year follow-up 
(a) Healthy population prospective results 
Heal thy I Diseased I Total 
--------------------------------!------------------------- ---------------
Type A 15n 
Type B 1532 
Total 3109 
Percentage diseased = 2.3 
Sensitivity = 71 
Specificity = 49 
RR = 2.5 
d' = .373 
Chi-squared test= 11.19 p < .0001 
52 1598 
21 1584 
73 3182 
Cb) Actual results for the recurrent CHO study of the WCGS at 4.5 years. 
Without Recurrent Disease I With Recurrent Disease Total 
--------------------------------1------------------------- ----------------
1 
Type A 114 I 23 137 
I 
--------------------------------!------------------------- --------------
1 
Type B 56 I 10 66 
I 
--------------------------------!------------------------- --------------
1 
Total 170 I 33 203 
Estimated results 
Sensitivity = 75% 
Specificity = 30% 
RR = 1.2 d' = .37 
Chi-squared = p > .05 
I 
Actual results 
Sensitivity = 70 
Specificity = 33 
RR= 1.1 d' = .14 
Chi-squared= p > .05 
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subjects are included in the study sample as a function of 
the age of the study sample. For the current paper, an 
example of how age bias could occur in research on TAB and 
CHD was used to illustrate how age bias can alter the 
magnitude of associations between risk factors and diseases. 
The DT model in Figure 2 can be used to describe age 
bias. Figure 2 illustrates how the percentage of Type A's 
and B's with CHD changes the sensitivity and degree of 
statistical association between TAB and CHD for the same men 
when they are examined at different ages in a healthy 
population prospective study. 
Figure 2 illustrates the development of CHD in a 
hypothetical sample of men who all eventually develop CHD. 
The degree of CHD in the sample is illustrated when the men 
are 40, 50 and 60 years old. Over half the sample has CHD 
when the patients are 60 years old. In contrast, less than 
a quarter of the individuals have CHD when the subjects are 
40 years old. 
The percentage of individuals with CHD who are Type A's 
varies with each age group. For the forty year olds, most 
of the individuals with CHD are Type A's. Thus, the 
sensitivity is very high. The new cases of CHD at age 50 
and 60 are the subjects that represented in the section of 
the distribution that is defined by £ as healthy at age 40 
but are defined as having CHD at age 50 (see Figure 2). In 
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Figure 2 
A DT Model of a Prospective Study 
Sample at age 
40 
Sample at age 
50 
Sample at age 
60 
-3 -2 
healthy 
subjects 
-1 
c 
0 1 2 
diseased 
subjects 
Notes. As in Figure 1, the distribution with more CHD 
represents Type A's, the distribution with less CHD 
represents Type B's and the x-axis indicates the severity of 
CHD. 
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the 50 year old group, a higher percentage of Type B's have 
developed CHD. Finally, more of the individuals who 
developed CHD after they were 50 are Type B's than Type A's. 
Figure 2 illustrates that most Type A's will incur CHD 
when they are younger than Type B's. Therefore, one would 
expect that most Type A's would be younger than Type B's who 
are selected for recurrent CHD studies. Individuals who 
develop CHD when they are younger tend to have less severe 
CHD than individuals who develop CHD when they are older. 
These younger and hardier individuals with CHD may survive 
longer after their initial MI and not die within the time 
frame of the recurrent CHD study. Therefore, one may find 
an inverse association between TAB and recurrent MI. 
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A REVIEW OF EXPLANATIONS FOR NULL FINDINGS 
Hypotheses Proposed by Previous Researchers 
At present, "no entirely satisfactory explanation for 
these null findings has been proposed (Dimsdale, 1988; 
Matthews, 1988). Several hypotheses have been forwarded. 
The current section frames these hypotheses in terms of the 
DT model. 
Diseased based spectrum (DBS) bias. Matthews (1988) 
provided one clue to a possible explanation. She noted that 
most of the null findings have occurred in high risk 
studies. In support of her hypothesis, Miller et al. 
(1988) found evidence suggesting that DBS bias has produced 
the null findings in research on TAB in angiography studies. 
Perhaps, DBS bias accounts for some of the confusion in 
research on TAB and CHD. That is, high risk studies have 
DBS bias. Therefore, high risk studies find null results 
because DBS bias attenuates correlations between TAB and CHD 
in these studies. In contrast, studies not vulnerable to 
DBS bias find positive results. 
Selection bias. There are other possible explanations 
for the trend towards null findings in research on TAB and 
CHD. The study designs that have been used in research on 
TAB and CHD are vulnerable to a number of different types of 
selection biases (Matthews, 1988). Thus, the method used to 
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select subjects may be associated with the magnitude of the 
g' between TAB and CHO. 
Several third variables have been implicated in 
research on TAB and CHO. For example, some (e.g., Rosenman, 
1986) have suggested that the culture or sex of the study 
population may mediate the strength of the relationship 
between TAB and CHO. 
Insufficient sample size. Booth-Kewley and Friedman 
(1987) proposed another plausible explanation for the null 
findings. Their research suggests the null findings may 
have occurred because the correlation between TAB and CHO is 
low. That is, some studies may have used a small sample 
size that lacked sufficient statistical power to detect the 
presence of the low correlation between TAB and CHO. 
Disease criteria. The location of the £ can influence 
the strength of the association between two variables 
(Rorer, Hoffman, & Hsieh, 1966). Each different disease 
criteria has a different g. Therefore, different disease 
criteria may influence the magnitude of the relation between 
TAB and CHO. In fact, Miller et al. (1988) reported 
evidence suggesting that different methods of defining CAD 
influence the magnitude of the relation between TAB and CAD. 
Indicator of TAB. Many researchers (e.g., Rosenman, 
1986; Williams et al., 1988) have suggested that the 
magnitude of the relationship between TAB and CHO may vary 
for different measures of TAB. In terms of the DT model, 
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the g' between a measure of TAB and CHO may vary for 
different measures of TAB. 
The current Research 
The current research attempts to identify the study 
characteristics (i.e., high risk studies, method used to 
select subjects, sample sizes, culture, sex, disease 
criteria, indicator of TAB) that are associated with null 
findings by a quantitative review. In addition, reanalyses 
of some studies are conducted to test whether the signs of 
DBS bias identified by Miller et al. (1988) are present in 
all types of high risk studies. The presence of these signs 
would suggest that DBS bias has produced the null findings 
in high risk studies. 
The current research is theoretically important because 
a OT model is developed and tested that can be used to 
identify subject selection biases in research on TAB and 
CHO. In addition, the current research attempts to identify 
study design characteristics that play an important role in 
mediating the strength of the relationship between TAB and 
CHO. These mediating variables may have important 
theoretical implications for understanding why TAB has been 
found to be associated with CHO in some studies. 
The current research also has practical significance. 
The identification of the study design characteristics that 
mediate the relationship between TAB and CHO may lead to an 
increased understanding of the reasons for the trend towards 
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null findings. In addition, subject selection biases may 
produce misleading results. The current research attempts 
to identify study designs that lead to misleading findings. 
Therefore, the current research has implications for the 
types of study designs that future researchers can use to 
obtain the less biased estimates of the magnitude of the 
relationship between TAB and CHD. 
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METHOD 
Locating Studies 
Most of the studies included in the current review have 
been used in previous reviews (Booth-Kewley and Friedman, 
1987; Matthews, 1988; Miller et al., 1988). Additional 
articles were found using Booth-Kewley and Friedman's (1987) 
procedures for locating studies. Briefly, these procedures 
include searching through journals that have published known 
articles and using computerized searches such as 
Psychological Abstracts and Medicus Indicus to find new 
articles. An attempt was made to include all studies that 
were published before 1989. Appendix A includes a list of 
new articles presented in neither Booth-Kewley and 
Friedman's, Miller et al.'s nor Matthews' reviews. 
Criteria for Including Articles 
Study selection criteria. Studies were included in the 
current review only if an article reported an attempt to 
find a statistical relation between CHO and some measure of 
TAB. In addition, the current review was limited to 
articles published in the English language. For the current 
research, only used at one of three types of indicators of 
CHO were used in the current study: (a) MI, (b) MI or angina 
(this category is referred to as CHO for the remainder of 
this paper) or (c) CAD from the results of an angiography. 
This selection criteria for CHO is slightly narrower than 
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the criteria used by Booth-Kewley and Friedman (1987). In 
contrast, to Booth-Kewley and Friedman, studies that 
assessed CHO by infrequently used disease outcomes were not 
included in the current review. For example, only a few 
studies (see Booth-Kewley & Friedman, 1987) have used angina 
as a disease outcome. For such studies, insufficient data 
were available to perform the detailed reanalyses and 
comparisons across different study designs conducted in the 
current review. 
Similarly, an insufficient number of studies were 
available to examine other psychological predictors of CHO 
(e.g., hostility, depression or subcomponents of TAB such as 
time urgency). Thus, studies that only used these predictor 
variables were not included in the current review. 
The Friedman et al. (1986) true experimental study 
(Brackett & Powell, 1988) is not included in the current 
review. This report collapsed results across a treatment 
and control group. This analysis strategy is inappropriate 
because the treatment successfully modified TAB. Therefore, 
collapsing across treatment and control conditions confounds 
the results. 
In addition, the results of one study (Williams et al., 
1988) were not included because this study was a follow-up 
of the Williams et al. (1980) study and not an independent 
study. The findings of the earlier study were used because 
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a correlation coefficient (~) could be calculated from the 
1980 report and not from the 1988 report. 
Finally, three studies (Friedman & Rosenman, 1959; 
Rosenman & Friedman, 1961; Schwertner, Troxler, Uhl, & 
Jackson, 1984) selected extreme Type A's and B's for study. 
selecting extreme groups is a useful method to insure that 
the constructs of interest are represented in the sample. 
However, selecting extreme groups also increases the 
magnitude of the ~ between the two variables. In fact, all 
three studies found the largest ~·s between TAB and CHO of 
any of the studies included in the current review. Thus, 
the results of these studies support the hypothesis that TAB 
is associated with CHO. However, the ~·s for these studies 
are not comparable with other studies and so the results of 
these studies were not included in the current review. 
Selection criteria for prevalence estimates. The sex 
or age composition of the sample may mediate the strength of 
association between TAB and CAD (Rosenman, 1986). To avoid 
the problem of confounding results for sex and age, the 
current research only used prevalence estimates of TAB from 
studies of middle-aged men. 
Selection criteria for studies used to test for the 
presence of DBS bias. The current research only tested for 
signs of DBS bias in studies that assessed TAB by the SI. 
There were two reasons why only these studies were examined. 
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First, the SI is the measure of TAB that is the most highly 
associated with CHD (Booth-Kewley & Friedman, 1987). 
Second, only studies that assessed TAB by the SI 
presented their results in sufficient detail for reanalysis. 
The SI has often been treated as a dichotomous variable. 
Therefore, the results have been presented in contingency 
tables that yield sufficient information for reanalysis. In 
contrast, most studies that used self-report measures of TAB 
have typically reported their results only in terms of tests 
of significance that provide insufficient information for 
reanalysis. 
Statistical Analyses 
Use of biserial and tetrachoric r coefficients. In the 
current review, the correlation coefficient (~) was used as 
the indicator of effect size. The ~ was used so as to allow 
comparison with other meta-analyses of research on TAB and 
CHD that used~ to indicate the effect size (e.g., Booth-
Kewley & Friedman, 1987). The Pearson~ underestimates the 
degree of association between two variables when the base 
rate for an artifactually constructed dichotomous variable 
is low (see Cohen & Cohen, 1984; Hunter, Schmidt & Jackson, 
1982; Kemsey, Dunlap & Griffeth, 1988). Both TAB and CHD 
are artifactually constructed dichotomous variables. In 
prospective and population studies, the base rate for CHO is 
low. Therefore, the magnitude of the Pearson ~ between TAB 
and CHD would vary with type of study design even if the 
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magnitude of the actual ~ between TAB and CHO does not vary 
with study design. To avoid the base rate problem, biserial 
and tetrachoric r's were calculated from the results 
reported in the original studies. The magnitude of these 
coefficients is not influenced by the base rate. The 
biserial coefficient is used when one variable is 
dichotomous and one variable is continuous. The tetrachoric 
coefficient is used when both variables are dichotomous. 
Controlling for sampling variability. A weighted mean 
~ (WMR) was estimated by multiplying each individual study ~ 
by the study sample size and taking the average of the 
products. Matthews (1988) and others (e.g., Hedges & Olkin, 
1985; Hunter et al., 1982) have argued that the weighted 
mean is more appropriate than an unweighted mean as an 
indicator of the average effect size across a series of 
studies. The WMR adjusts for the sampling variability 
produced by studies of different sample sizes. Sampling 
variability could be a severe problem in the current 
research because sample sizes varied from 25 to 11,364. 
Methods used to sum r's. Eleven studies reported null 
results with no specific information that could be used to 
calculate an ~· As recommended by meta-analysts (Hedges & 
Olkin, 1985), the~ was considered to be equal to zero in 
these cases. To compute WMR's, ~·s were transformed to 
Fisher ~·s, weighted by study sample size and then 
transformed back into the~ metric3 • 
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Testing for inter-study variability. An inter-study 
variation index (IVI; Hunter et al., 1982) was used in the 
current research. to ascertain the homogeneity of summed 
study effect sizes. The IVI is an index of the percentage 
of inter-study variation in study ~ that is beyond the 
amount explained by sampling variability. A large IVI 
suggests that the studies are not comparable and the 
magnitude of the WMR may be misleading. 
Study Variables 
Disease criteria. Four different disease outcomes were 
examined in the current review: (a) CHD, (b) MI, (c) CAD and 
(d) fatal MI. In addition, the CAD category was divided 
into several subcategories according to the CAD scoring 
method; these subcategories for CAD were used because 
different CAD scoring methods appear to have a small 
influence on the magnitude of the ~ between TAB and CAD (see 
Miller et al., 1988). 
Measures of TAB. Measures of TAB were divided into 
three categories: (a) the structured interview (SI; 
Rosenman, 1978), (b) the Jenkins Activity Survey (JAS; 
Jenkins, Zyzanski, & Rosenman, 1971) and (c) other self-
report measures. The JAS has been used in a sufficient 
number of studies to compare results across different study 
designs. Therefore, studies using the JAS are considered 
separately from other less frequently used self-report 
measures. 
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study design. Every study was classified as either a 
cross-sectional or prospective design, and as either a 
healthy population or high risk design based on the 
definitions presented in the review section. In addition, 
study designs were classified according to how subjects were 
recruited for study. 
Culture. The prevalence of TAB appears to be related 
to culture (Rosenman, 1986). Therefore, the results were 
examined separately for studies conducted within the United 
States and studies conducted in other countries. 
Sex. The sex of the subject may mediate the strength 
of the relationship between TAB and CHD because sex is 
correlated with both TAB (Rosenman, 1986) and CHD. Although 
most studies only examined men, some studies included women. 
For studies reporting results for men and women separately, 
only the results for men were used when summing ~·s to 
calculate WMR's. In studies that only reported combined 
results for both men and women, the percentage of the sample 
that was female was recorded and an attempt was made to 
determine if the percentage of females in these studies was 
correlated with the magnitude of the study ~ between TAB and 
CHD. An association between sex and study ~ would suggest 
sex mediates the relation between TAB and CHD. 
Year of publication. The year 1978 was chosen as a 
point at which to divide the studies into two groups. 
Studies published before or during 1978 were considered to 
p/(: :;.:~·--TOiYh~ 
.. 'i C1-,, ,,., 
.. _. io/. I \ 
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be early studies and studies published after 1978 were 
categorized as more recent studies. This year was chosen 
because it was the year of the NHLBI's review. Presumably, 
any influences over time occur because of historical trends. 
Therefore, the time the data were collected would be a more 
exact indicator of the history of the study. Unfortunately, 
many studies did not report this information so the year of 
publication was chosen as the best available proxy. 
The findings of some studies were reported in several 
articles in which some were published before and others 
after 1978. In these cases, the study was classified as 
occurring before 1978 because the earliest publication date 
is nearest to the time the data were collected. 
Unit of Analysis 
One purpose of the current review was to determine why 
some studies have reported null findings. Presenting 
results in smaller subunits (e.g., estimating different ~·s 
for different age groups within a single study) would not be 
consistent with this purpose. That is, identifying 
differences produced by different subpopulations is not the 
purpose of the current research. Therefore, ~·s were not 
estimated for subgroups within a single study. A total of 
61 independent studies were included in the current review. 
When summing across ~·s, only the results of 
independent studies were combined. When a single study 
reported more than one result, several decision rules were 
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used to decide which ~ should be used for the meta-analysis. 
First, previous research (Booth-Kewley and Friedman, 1987) 
has established that the ~·s between TAB and CHO and between 
TAB and MI are similar. Therefore, the results of studies 
that used either of these two disease outcomes were 
combined. Only the ~ for the CHO outcome was used to avoid 
double weighting in studies that reported results for both 
CHO and MI. In addition, only the results of the longest 
follow-up period were used to calculate a ~ to insure that 
the results of prospective studies were not double weighted. 
Some of the analyses presented in the current review 
examined the association between study characteristics 
(e.g., study design) and number of positive (statistically 
significant) versus null findings. A few studies were 
difficult to code for these analyses because a ~ could be 
calculated for more than one study characteristic. For 
example, a study might be weighted twice if the results were 
reported for both prospective and cross-sectional designs or 
for two different measures of TAB. In these cases, the 
study was treated as one finding if the results were the 
same for all study characteristics; otherwise, the study was 
not used in the analysis. The exclusion of studies did not 
lead to missing data problems. No more than three studies 
were excluded from an analysis because the studies reported 
mixed results. 
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Testing for the Presence of DBS Bias 
DBS bias is defined as occurring when the range of 
disease in the sample has been restricted to subjects with 
moderate to severe disease (Miller et al., 1988). Thus, DBS 
bias is present in studies in which completely healthy 
individuals are not selected for study. DBS bias produces 
null findings to the extent that the level of disease in the 
high risk comparison group is equivalent to the level of 
disease in the diseased group. As the spectrum of disease 
across the two groups narrows, the percentage of Type A's in 
the high risk comparison and diseased groups becomes 
equivalent so there is no significant difference in the 
percentage of Type A's found in these two groups. 
There are two signs of DBS bias that researchers can 
test for. One would have evidence to suggest that DBS bias 
has produced the null findings in high risk studies if these 
signs are present. One sign of DBS bias is a high 
percentage of Type A's found in both the diseased and 
comparison groups used in high risk studies and a low 
percentage of Type A's found in healthy populations. This 
pattern of results would suggest more Type A's than Type B's 
develop CHO. However, this finding is obscured in high risk 
studies in which all of the subjects have some CHO because a 
high percentage of Type A's are found in both the high risk 
comparison group and the diseased group in high risk 
studies. 
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A second way to test whether DBS bias may have produced 
the low ~ in recurrent CHO studies is to determine if range 
restriction can account for the reduced ~·s found in these 
studies. The ~ obtained from recurrent CHO studies can be 
considered to have two parts: a part produced by range 
restriction and a part not attributable to range restriction 
(e.g., sampling variability, other biases). One can use a 
formula that estimates the attenuation in ~ that would occur 
in a high risk study given a healthy population ~ and an 
estimate of the percentage of the population that is 
excluded from the study sample. This formula is referred to 
as a range restriction formula. One can compare the ~ 
obtained from the range restriction formula with the actual 
~ between TAB and CHO. A significant difference between the 
estimated and actual ~·s would suggest that study 
characteristics other than range restriction have 
contributed to the small ~·s found in high risk studies. In 
contrast, range restriction may have produced the smaller 
~·s found in high risk studies if the estimated results are 
not significantly different from the actual results. 
Testing for a higher percentage of Type A's in high 
risk populations. The binomial ~ test (for a discussion, 
see Miller et al., 1988) was used in the current research to 
determine whether significantly higher percentages of Type 
A's were present in high risk populations than in healthy 
populations. The binomial ~ test requires an accurate 
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estimate of the percentage of Type A's found in a healthy 
population. Therefore, a review of the literature was 
conducted to obtain an accurate estimate. 
Estimating the reduction in the magnitude of the r 
produced by range restriction in recurrent CHD studies. 
Alexander, Carson, Alliger and Barrett (1985) provide a 
range restriction formula that can be used to estimate the 
reduction in r in high risk studies4 • The formula is used 
in the current research to estimate the reduction in r 
between TAB and CHD in a recurrent CHD study from the r 
obtained in a healthy population study. 
The range restriction formula requires a healthy 
population estimate of the r between a disease and a risk 
factor. Unfortunately, no estimates of the r between TAB 
and CAD from healthy population studies are available. 
Therefore, no range restriction formulas were calculated for 
angiography studies. For recurrent CHD studies, the range 
restriction formula requires an estimate of the percentage 
of healthy subjects who are expected to incur a MI in the 
future and an estimate of the r between TAB and MI found in 
a healthy population study. The estimates used for the 
range restriction formula for the recurrent CHD studies were 
from the healthy population prospective results of the WCGS 
(4.3% MI rate and r = .33). 
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Distinguishing between DBS bias and other subject 
selection biases. DBS bias can often be distinguished from 
other types of s~bject selection biases (Miller et al., 
1988). One would suspect that DBS bias has produced null 
findings when the percentages of Type A's across diseased 
and comparison groups only vary with whether the study used 
a high risk or healthy population design. Alternatively, 
one would have evidence that other subject selection biases 
are present if the study ~·s vary with the way subjects were 
selected. For example, high risk studies have selected 
subjects with CHO by four different methods: (a) selection 
on the basis of their risk factor status, (b) selection by 
the results of an angiography in which subjects were 
diagnosed as having clinically significant CAD, (c) 
selection because an individual developed CHO during the 
course of a prospective study or (d) selection because one 
worked in a company participating in a study. 
The percentage of Type A's found in these high risk 
studies would be expected to vary with these different 
subjects selection methods if subject selection biases other 
than DBS bias have produced the null findings in high risk 
studies. To determine the extent to which subject selection 
biases may have reduced the relation between TAB and CHO, 
the current research examined whether the prevalence of TAB 
and the ~ between TAB and CHO varied with the method used to 
select subjects. One would have evidence that DBS bias has 
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produced the null findings in high risk studies if the ~ 
between TAB and CHO and the prevalence of TAB varies with 
whether the study was high risk or healthy population. 
Other subject selection biases may be present if the ~ 
between TAB and CHO and the prevalence of TAB varies with 
how the subjects were selected. 
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RESULTS 
study Characteristics Associated with the Trend Towards Null 
Findings 
The results of the current research support Booth-
Kewley and Friedman's (1987) finding of a significant trend 
towards null findings in research on TAB and CHD. As 
indicated by the Fisher exact test, studies included in the 
current review were significantly more likely to report 
positive findings before 1979 for both the SI (p<.05) and 
self-report measures (p<.005). There were four times as 
many studies reporting null findings after 1978 for studies 
that assessed TAB by the SI and eight times as many studies 
reporting null findings for studies that used self-report 
measures. 
Table 3 illustrates that three types of studies have 
been associated with null findings: (a) high risk studies, 
(b) studies that used self-report measures and (c) studies 
that used fatal MI as a disease criterion. All three of 
these types of studies have been conducted more frequently 
after 1978. Thus, all three types of studies have 
contributed to the trend towards null findings. 
High risk studies. High risk studies accounted for the 
majority of the null findings. Among the 39 independent 
studies that reported null findings, 24 were high risk 
studies. High risk studies had significantly more null 
findings--by the Fisher exact test--than healthy population 
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Table 3 
summary of the Characteristics Studies with Null Findings 
HIGH RISK HEALTHY BOTH SELF-REPORT FATAL Ml 
SI STUDIES SELF-REPORT AND HIGH RISK 
Nl.lllber of studies with 
null findings 16 
Percentage of studies 
that reported null 
findings 
Percentage of studies 
published after 1978 
84 
81 
8 
30 
79 
17 8 
89 100 
87 100 
INADEQUATE 
SAMPLE SIZE 
2 
100 
UNKNOWN 
100 
Notes. The total nl.lllber of independent studies that reported more null results than positive 
results was 30. HIGH RISK SI STUDIES are studies that assessed TAB by the SI and used a high risk 
study design. HEALTHY POPULATION SELF-REPORT studies used a self-report measure and a healthy 
population study design. Two studies clearly used inadequate sample sizes. Appels and Mulder 
(1985) only examined 18 subjects with CHO. Keefe, Castell and Blumenthal (1986) had a total sample 
size of 25. The UNKNOWN collJ!n represents one study that did not fall into any of the other 
categories. INADEQUATE SAMPLE SIZE and UNKNOWN could be any studies in the sample. Therefore, the 
percentage of studies that reported null findings is left blank. The UNKNOWN study was a case-
control by Wielgosz, Wielgosz, Biro, Nichols, MacWilliam, and Haney (1988) that used the SI to 
assess TAB. 
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studies for all studies that assessed TAB by the SI (p < 
.005) and by self-report measures (p < .005). Overall, 24 
independent high risk studies reported null results, three 
reported mixed results and only four reported positive 
results. 
There was a trend towards null findings for all of the 
different types of high risk studies. Before 1979, three 
out of four angiography studies reported positive results. 
After 1978, only one study reported a positive result, three 
reported mixed results for different measures of TAB and 15 
reported null results. Similarly, only one of the five 
recurrent CHD studies were conducted before 1979. One study 
conducted after 1978 reported mixed results and the other 
studies reported null results. Finally, two studies that 
selected subjects on the basis of their traditional risk 
factor status also reported null findings and were published 
after 1978. In sum, most high risk studies were conducted 
after 1978 and reported null results. 
Healthy population studies that assessed TAB by the SI. 
In contrast to high risk studies, healthy population studies 
that used the SI were associated with positive findings. 
For studies that used the SI, six of eight reported positive 
findings. Although there has been an increase in the number 
of high risk studies in recent studies, there has not been 
an increase in the number of healthy population studies that 
assessed TAB by the SI in recent years. Only two 
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prospective studies used the SI to assess TAB since 1978. 
In one of these studies {Appels & Mulder, 1985), the sample 
size was clearly. insufficient {only 18 subjects with CHD) 
and the study reported null results. Thus, only one study 
in recent years has assessed whether the SI is a predictor 
of CAD and this study reported a positive result. 
Studies that assessed TAB by self-report measures. The 
use of self-report measures in healthy population studies 
has also contributed to null findings in recent years. For 
studies that used self-report measures, 15 of 26 studies 
reported positive findings, three studies reported mixed 
results, and eight reported null findings. Only three of 
eight healthy population prospective studies that assessed 
TAB by self-report measures since 1978 reported positive 
results. 
There has been an increase in the number of studies 
using self-report measures in recent years. For studies 
that used self-report measures, 19 of 26 healthy population 
studies were conducted after 1978. 
Table 4 presents the number of studies, percentage of 
significant findings, WMR's, IVI's, confidence intervals 
{CI's) for the WMR's and the study H for each type of study 
design and measure of TAB. The table illustrates how study 
design and measures of TAB are related to the percentage of 
significant findings and the magnitude of the WMR. 
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Table 4 
Findings for Each T~ of Studv Design 
Prospective Cross-sectional 
High risk Healthy population High risk Healthy population 
Recurrent Population Angiography Case- Population 
CHO Control 
Studies That Used the SI 
# of 
studies 4(4) 3(3) 13(11) 5(5) 1(1) 
" of positive 
findings 0 67 23 80 100 
114R .12 .33 .13 .35 .31 
IVI .001 .013 .168 .126 .000 
Cl .06- .18 .31-.35 .09- .17 .31-.39 .28-,34 
Total 
N 954 4,298 2,348 605 3,524 
Studies That Used the JAS 
# of 
studies 4(4) 7(4) 9(5) 7(7) 7(5) 
" of positive 
findings 2S 43 22 86 86 
114R .02 .04 .00 .26 .07 
IVI .013 .003 .027 .006 .004 
Cl - .02- .06 .03-.0S - .OS- .OS .20-.32 .OS-.09 
Total 
N 2,308 18,330 1,367 933 10, 101 
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Table 4 continued 
Prospective Cross-sectional 
High risk Healthy population High risk Healthy population 
Recurrent Population Angiography Case- Population 
CHO Control 
Studies That Used Other Self-report Measures 
# of 
studies 0 5(4) 8(3) 4(3) 3(3) 
% of 
positive 
findings 40 13 75 33 
WMR .03 .00 .21 .19 
!VI .015 .018 .031 .001 
Cl .01-.05 -.03-.03 .12- .30 .17-.21 
Total 
N 16,085 3,395 481 13,668 
Notes. # of studies = the nunber in parentheses represents the nunber of reports in which an r 
could be calculated. The nunber not in parentheses is the total nunber of studies; % of positive 
findings = the percentage of studies that reported a significant positive association between TAB 
and CHO; !VI =percentage of variation in r across studies that cannot be attributed to sampling 
error; Cl = 95% confidence interval; Total N = total nunber of subjects used to estimate the WMR's. 
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A small ~ between self-report measures of TAB and CHD 
appears to have produced some of the null findings. 
prospective studies that assessed TAB by self-report 
measures were consistently associated with small ~·s. The 
WMR's for these studies varied from .04 to .oo (see row in 
Table 4 labeled "WMR"). Many healthy population studies 
(30%; see Table 3) found null results. The reason for the 
larger WMR's in the cross-sectional healthy population 
studies is not clear5 • 
Studies that used fatal MI as a criterion. Table 5 
presents the results for studies that used fatal MI as a 
disease criterion. All eight studies found no statistically 
significant association between TAB and fatal MI. In most 
of these studies, the ~ between TAB and fatal MI was in the 
negative direction. Thus, using fatal MI as a criterion 
produces results that are markedly different from studies 
using other disease criteria. The use of fatal MI has 
contributed to the trend towards null findings because all 
eight studies were published after 1978. 
Evidence of DBS bias in High Risk studies 
Evidence of smaller r's in high risk studies. One 
would expect smaller ~·s in high risk studies than have been 
found in healthy population studies if DBS bias is present 
because DBS bias is a type of range restriction that may 
attenuate ~·s in high risk studies. In fact, the ~ between 
TAB and CHD does appear to be larger in healthy population 
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Table 5 
studies that Used Fatal MI as a Criterion 
Measure Author Year 
Healthy Population Prospective Studies 
SI Ragland 1988b 
Bortner 
FRHM 
Mann 
Eaker 
High Risk Prospective Studies 
SI 
SI 
SI 
JAS 
JAS 
Unique 
De Leo 
Shekelle 
Ragland 
Dimsdale 
Case 
Ruberman 
1987 
1988 
1985 
1985 
1988a 
1981 
1985 
1984 
N r 
3, 154 .09 
7,214 -.07 
337 -.27 
68 -.21 
3, 110 .03 
231 - .34 
189 
516 -.11 
2,320 
Notes. Measure = the measure of TAB used; Author = the first author of the article; Year = the year 
of publication of the article reporting the study findings; N =study sample size; FRHM =The 
Framingham Type A scale; Unique = a measure of TAB was used that has not been used in any other 
study. WMR's are not reported because of the substantial inter-study variation that is probably 
produced by the use of different measures of TAB. Appels and Mulder (1985) reported four fatal Ml 
cases in their sample. All four were Type A. Koskenvuo, Kaprio, Langinvainio and Romo (1983) 
reported an analysis of fatal MI in which only three subjects had fatal MI. 
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studies than high risk studies. There is a moderate r 
between the SI and CHO in healthy population studies (see 
row in Table 4 labeled "WMR"; prospective healthy population 
= .33; case control = .35; cross-sectional population = 
.31). These WMR's are among the largest ~·s presented in 
Table 4. In contrast, the WMR's for high risk studies that 
assessed TAB by the SI were smaller (recurrent CHO= .12; 
angiography= .13). A similar pattern of smaller ~·sis 
found in studies that used self-report measures (see Table 
4). Evidence of a lower percentage of Type A's in healthy 
populations. One would expect a lower percentage of Type 
A's in healthy populations than among individuals with CHO 
if TAB is associated with CHO. Table 6 presents the 
percentage of Type A's found in all healthy population 
studies that assessed TAB by the SI and that reported 
results in sufficient detail to estimate the prevalence of 
TAB. The results in Table 6 indicate that the percentage of 
Type A's found among healthy middle-aged American men is 
46%±1% (H = 5,383; IVI = .001). 
Evidence for the influence of culture. TAB is 
supposedly a product of the aggressive American lifestyle 
(Rosenman, 1986). In support of this hypothesis, the 
percentage of Type A's found in populations outside the 
United States appears to be somewhat lower. In these 
studies, the percentage of Type A's varied from 27% to 52% 
and was generally lower than the studies conducted in the 
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united states (see Table 6 column labeled"% of Type A's"). 
similarly, the percentage of Type A's in high risk studies 
conducted outside the United States (60%±3%; N=l,111; IVI = 
.016) was lower than in studies conducted in the United 
states (see Table 7). 
In spite of these base rate differences, the ~·s 
between TAB and CHO in countries that were conducted outside 
the United States are similar in magnitude to those studies 
that were conducted in the United States. The IVI's for the 
WMR's presented in Table 4 are generally very small 
suggesting that there is little inter-cultural variation in 
WMR's. For example, there appears to be no substantial 
difference in the ~ between healthy population studies 
conducted in the United States that assessed TAB by the SI 
(WMR = .32±.02; N=3,443; IVI = .009) and studies conducted 
outside the United States (WMR = .36±.03; N=l,460; IVI = 
• 004) • 
In sum, cultural differences among subjects do not 
appear to influence the magnitude of the ~ between TAB and 
CHO. Thus, WMR's are reported for all countries combined. 
However, culture is related to the prevalence of TAB. 
Therefore, prevalence rates for the SI are only reported for 
studies conducted in the United States in the current paper. 
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Table 6 
The Prevalence of Type A's in Healthy Population Studies that Assessed TAB by the SI 
Studies Conducted in the United States 
Author Year X of Type A's(N) 
Keith+ 1964 31(69) 
Caffrey 1969 42(1521) 
Rosenman 1975 49(2897) 
Bryne 1985 46(582) 
Moss 1986 47(314) 
Studies Conducted outside the United States 
Author Year x of Type A's(N) Country 
Kittel 1978 38(726) Belgi1.111 
Verhagen+ 1980 43(58) Netherlands 
Orth-Gomer+ 1980 27(48) Sweden 
Appels 1987 48(191) Netherlands 
Wielgosz+ 1988 52(71) Canada 
Notes. Author = the first author of the article that reported the study findings; Year = the year 
of publication of the article reporting the study findings; X of Type A's(N) =the nl.lllber not in 
parentheses indicates the percentage of Type A's and the nunber in parentheses indicates the nunber 
of subjects the percentage estimate was based on; Country = the country in which the study was 
conducted. The weighted mean percentage of Type A's for studies conducted in the U.S.A. was 46X C,tf 
= 5,383). The weighted average prevalence of TAB for countries other than the United States was not 
calculated because of substantial intra-study variation (IVI = .307). 
51 
Table 7 
percentase of Type A's Found in Hish Risk Studies 
Author Year Disease X Type A's in Country 
criteria 
---
Diseased Comparison 
Group Group 
Angiography Studies 
Blunenthal 1978 TOTCI 80(64)* 44(78) U.S.A. 
Krantz 1981 TOTCI 78(49)* 71 (34) U.S.A. 
Dembrowski 198S TOTCI U.S.A 
Blunenthal 198S TOTCI U.S.A 
Frank 1978 >SOX 80(118)* 4S(29) U.S.A 
Krantz 1979 >SOX 67(4S)* U.S.A. 
Dimsdale 1979 >SOX 64(87)* 62(16) U.S.A. 
Scherwitz 1983 >SOX U.S.A. 
Willi ams 1980 >75X 79(28S)* 67(139)* U.S.A. 
Arrowood 1982 >75X U.S.A. 
Siegman 1987 >75X U.S.A. 
Blunenthal 1987 >75X 60(92)* 76(21) U.S.A. 
Murphy 198S U.S.A. 
Langeluddecke 1988 >SOX 46(40S) 41(114) Australia 
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Table 7 continued 
Recurrent CHO studies 
Rosenman 1967 CHO 70(33)* 67(170)* U.S.A. 
Krantz 1979 CAD nc13> 62(32)* U.S.A. 
Rechnitzer 1983 Ml 76(79)* 70(539)* Canada 
De Leo 1986 Ml 44(88) 43(51) Italy 
Studies that selected on the basis of risk factor status 
Shekel le 
Bel maker 
1985 
1976 
Ml 
CHO 
73(129)* 74(2991)* U.S.A. 
68(34)* 70(44)* U.S.A. 
~· * = the test of the hypothesis that the percentage of Type A's is greater than 47% is 
statistically significant by the binomial~ test that is corrected for continuity and adjusted by 
the Bonferroni criteria (Individual alpha = .05/12 = .004); Author = the first author on the article 
that reported the study findings; Year= the year of publication of the findings of the study; CAD 
= increase in severity of CAD; >SOX and >75% are CAD scoring methods in which only subjects with no 
occluded coronary arteries greater than 50 or 75% occlusion are classified as healthy; TOTCI is 
another CAD scoring method (Blumenthal et al., 1985); X of Type A's= the nunbers not in 
parentheses indicate the percentage of Type A's and the riuii>ers inside the parentheses indicate the 
riuii>er of subjects used to estimate the percentages of Type A's. 
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Evidence of a higher prevalence of TAB in high risk 
g_omparison and diseased groups. One would expect that a 
higher percentage of Type A's would be found in both the 
high risk comparison and diseased groups in high risk 
studies than in healthy populations if DBS bias has produced 
the null findings in high risk studies. The findings of the 
current research support this hypothesis. 
Table 7 presents the percentages of Type A's in the 
diseased groups and the high risk comparison groups in high 
risk studies. In addition, Table 7 displays the binomial z 
test of the difference in the percentage of Type A's found 
in healthy population studies versus diseased comparison 
groups. A statistically significant binomial z test is 
indicated by a "*" in Table 7. The upper bound of the 
confidence interval (47%) of the percentage of Type A's 
found in the healthy population studies was used as an 
estimate for the binomial z tests conducted in the current 
research. The test of the hypothesis that the percentage of 
Type A's is greater than 47% is statistically significant by 
the binomial z test was corrected for continuity and 
adjusted by the Bonferroni criteria (Individual alpha = 
.05/12 = .004). 
For studies conducted in the United States, a 
significantly higher percentage of Type A's than the 47% 
healthy population estimate were found in all but one study. 
A small sample size appears to be the reason for the lack a 
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statistical significance in the one study {H = 13). The 
percentage of Type A's found in this study is similar to the 
percentages found in the other studies. Thus, this study 
may also have had a statistically significant result if a 
larger sample size was used. In addition, the high risk 
comparison groups with sufficient sample sizes to obtain 
significant results had significantly more Type A's than 
found in healthy populations. 
The percentage of Type A's found in the high risk 
comparison groups is similar to that found in the diseased 
groups. For the 1,349 subjects with diagnosed CHD or CAD in 
the studies conducted in the United States, 70% {±2%; 
IVI=.006) were Type A's; a much higher percentage of Type 
A's than the 46% found in healthy populations. For the high 
risk comparison groups, the percentage of Type A's was 
similar to the diseased groups varying from 62% to 76% {see 
columns labeled"% Type A's Comparison Group"). 
Evidence of range restriction. DBS bias is a type of 
range restriction. Thus, one would expect that range 
restriction formulas could estimate the reduced ~·s found in 
recurrent CHD studies if in fact DBS bias has reduced ~·s in 
these studies. The ~ calculated from the range restriction 
formula is .14 for recurrent CHD studies that assessed TAB 
by the SI. To estimate the reduction in ~ in high risk 
studies that used the JAS, the healthy population ~ between 
the JAS and CHD was assumed to be .04; this is the WMR for 
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all healthy population prospective studies (see Table 4). 
The estimated ~ for studies that assessed TAB by the JAS is 
.02. 
Table 8 presents the expected ~·s estimated from the 
range restriction formula, the observed ~·s, the standard 
error associated with the 95% confidence interval of the 
observed ~·s and the absolute value of the difference 
between the expected and observed ~·s. Recall that the 
range restriction formulas used to derive the expected ~·s 
only use information regarding the ~ found in healthy 
populations and the percentage of healthy subjects that have 
been excluded from the sample. Thus, the range restriction 
formula estimates the degree of range restriction that would 
be expected in a high risk sample given that a certain 
percentage of low risk subjects has been excluded from the 
study sample. Therefore, the restriction in range formula's 
results is independent of the actual study findings. The 
differences between the expected and observed ~·s in Table 8 
are always smaller than the standard error. That is, the 
expected ~·s are within the 95% confidence intervals of the 
observed ~·s in every study. Thus, the expected ~·s 
estimated from the range restriction formulas accurately 
estimate the magnitude of the ~ between TAB and CHO found in 
recurrent CHO studies. These results support the hypothesis 
that DBS bias has produced the reduction in ~ found in 
recurrent CHO studies. 
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Table 8 
CQ!IP8rison of Observed r's between TAB and CHO in Recurrent CHO Studies with Expected r's 
Author N Expected Observed Standard Absolute value 
r r 
Studies that assessed TAB by the SI 
Rechnitzer 618 .14 .12 
De Leo 88 .14 .17 
Rosenman 203 .14 .05 
Weishted mean 909 .14 .11 
Studies that assessed TAB by the JAS 
Jenkins 98 .02 .07 
Shekel le 2070 .02 .02 
Appels 70 .02 -.11 
Weighted mean 2238 .02 .02 
error 
.08 
.21 
.14 
.20 
.04 
.24 
of the difference 
.02 
.03 
.09 
.03 
.05 
0 
-.13 
0 
Notes. N = s~le size; Expected r = the r estimated by the range restriction fornula; Observed r 
= the r reported in the study; Standard error = the 95X confidence interval; Absolute value of the 
difference = the absolute value of the difference between the expected and observed r. Follow-up 
results for the 8.5 year WCGS for the JAS were not presented in a manner in which an r could be 
estimated. Therefore, the 4.5 year follow-up results by Jenkins et al. (1971) are reported in Table 
8. 
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The base rates of MI in prospective studies of CHO 
conducted in this review varied from 6.2% to 2.2%. To test 
whether the results were influenced by the 4.3% base rate 
estimate used to calculate the expected ~ by the range 
restriction formula, base rates from 10% to 1% were used to 
calculate different expected ~·s from the range restriction 
formulas. No observed ~ was significantly different from 
any of the expected ~·s. Thus, the findings for the range 
restriction formulas appear to be robust with regards to the 
estimate of the base rate of CHO that is used. 
Evidence of selection biases. One would expect the 
prevalence of TAB to vary with the way subjects were 
selected if selection biases have influenced research on TAB 
and CHO. The percentages of Type A's were similar across 
all different subject selection methods for subjects with 
CHO in the studies included in the current review. Subjects 
were selected by four different methods: (a) selection on 
the basis of risk factor status (72±7% ; H = 163; IVI ~ 
.065), (b) selection by the results of an angiography in 
which subjects were diagnosed as having clinically 
significant CAD (74±3%; H = 740; IVI = O), (c) selection 
because the individual developed CHO during the course of a 
prospective study (69±6% ; H = 257) and (d) selection 
because one worked in a company participating in a study 
(71±7%; li = 113). 
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The prevalence of TAB in healthy population comparison 
groups is consistent across several different methods of 
subject selection (see Table 6). These studies selected 
subjects from towns, factories, monasteries and hospital 
wards that included patients without CHO. The findings 
suggest that the method used to select subjects does not 
greatly influence the prevalence of TAB in research on TAB 
and CHO. 
In contrast, there was variation in the prevalence of 
TAB across three different types of high risk comparison 
groups: (a) studies that selected subjects with the 
traditional risk factors (74%±1%; H = 3,035; IVI = O), (b) 
studies that reported the results of the two earliest 
angiography studies (44%± ; H = 107 ; IVI = 0) and (c) 
studies that reported the results of other high risk studies 
(67%±4%; H = 412 ; IVI = 0). The two earliest angiography 
studies used subject selection methods that are similar to 
more recent studies. Thus, subject selection methods cannot 
account for the differences between these two studies and 
later angiography studies. However, there appears to be a 
slight increase--74% versus 67%--in the percentage of Type 
A's found in studies that select subjects on the basis of 
their risk factor status. 
The WMR's varied only with whether the sample was 
healthy population (prospective healthy population = .33; 
case control = .35; cross-sectional population = .31) or 
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high risk (recurrent CHO= .12; angiography= .13). The 
IVI's for high risk and healthy population studies were all 
low (see Table 4). Thus, different methods of subject 
selection other than the high risk versus healthy population 
distinction do not appear to influence the prevalence of TAB 
or the magnitude of the ~ between TAB and CHD6 • Only the 
two studies that selected subjects on the basis of their 
risk factor status appear to have significantly more Type 
A's in their high risk comparison groups than have been 
found in other high risk comparison groups. 
Evidence of a trend towards more DBS bias in 
angiography studies. Miller et al. (1988) suggested that 
screening procedures for diagnostic angiography have 
improved in recent years so that fewer completely healthy 
subjects have been selected for study. Thus, there has been 
an increase in the extent of CAD in the diseased comparison 
groups in angiography studies in recent years. Miller et 
al. proposed that this restriction in range of CAD severity 
has attenuated ~·s between TAB and CAD in recent years. 
In fact, the percentage of Type A's in the diseased 
comparison group in angiography studies has increased. The 
earliest two angiography studies had percentages of Type A's 
(45% and 44%; see Table 7) in their diseased comparison 
groups that are similar to the percentages of Type A's that 
have been found in healthy populations (see Table 5). More 
recent angiography studies have reported higher percentages 
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of Type A's in their diseased comparison groups (see Table 
7) • 
The increase in the percentage of Type A's in the 
diseased comparison groups has apparently produced the null 
findings in angiography studies. Only three studies in 
Table 7 reported positive findings. The two angiography 
studies published in the United States before 1979 reported 
positive results. Only one other study (Williams et al., 
1980; H=424) achieved a statistically significant result by 
using a larger sample size than other angiography studies. 
In further support of the hypothesis that screening 
procedures have improved, the angiography study ~·s are 
inversely correlated with year of publication within each 
type of CAD scoring method (see Table 9). The IVI for 
angiography studies that assessed TAB by the SI is large 
(.168) because of a trend towards smaller ~·s in recent 
years. 
Finally, one would expect the percentage of 
angiography patients with diagnosed CAD would increase if 
diagnostic screening procedures have improved. In fact, the 
percentage of individuals diagnosed as having CAD in the 
sample is nearly perfectly correlated with the year of 
publication (see Table 9). In fact, the Spearman rank ~·s 
between the percentage of individuals with CAD and year of 
publication is 1.0 for the studies using the TOTCI method 
and the >75% occlusion scoring methods. 
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Only two findings were inconsistent. First, Krantz 
found slightly fewer patients with CAD and a slightly higher 
correlation between the SI and CAD than Dimsdale did a year 
earlier (see Table 9). Both studies were associated with 
small sample sizes. Therefore, the discrepancy may simply 
be the result of sampling error. Second, Langeluddecke 
found a lower percentage of subjects with CAD. The lower 
percentage of patients with CHO found in this study may have 
been the result of a lower prevalence of CAD in Australia. 
There appears to be no relation between sex and the 
magnitude of the~ between TAB and CAD (see Table 8). 
However, an insufficient number of studies other than 
angiography studies have included women. Therefore, the 
current research could not determine whether the magnitude 
of the relationship between TAB and CHO is influenced by 
subject sex for studies that did not use angiography as a 
disease criteria. 
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Table 9 
Year of Publication, X Ill and r in Angiography Studies that Assessed TAB by the SI 
Author 
TOTCI Scoring Method 
Blllllenthal 
Krantz 
Dembrowski 
Blllllenthal 
>SOX Occlusion Scoring Method 
Frank 
Dimsdale 
Krantz 
Scherwitz 
Langeluddecke 
Year 
1978 
1981 
1985 
1985 
1978 
1979 
1981 
1983 
1988 
x ill 
45 
59 
69 
73 
80 
84 
78 
>85 
78 
r 
.57 
.14 
.09 
-.09 
.55 
.03 
.07 
.03 
.08 
63 
X female 
44 
8 
25 
31 
16 
0 
0 
0 
21 
Table 9 continued 
--------------------------------------------------------------------------
Author 
>75X Occlusion Scoring Method 
Blunenthal 1975 
Williams 1980 
Arrowood 1982 
Siegman 1987 
Blunenthal 1987 
Year 
51 
70 
78 
82 
X i LL 
.67 
.25 
-.01 
-.29 
r 
44 
28 
26 
24 
X female 
Notes. Author = the first author of the article that reported study findings; Year = the year of 
publication of the study; X ill = the nuit>er of patients that were diagnosed as having significant 
CAD; X females= the percentage of women in the sa...,Le;. The r's reported in this table vary 
slightly from Miller et al.'s (1988) report that reported adjusted r's. 
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DISCUSSION OF STUDY FINDINGS 
Research on TAB and CHO has been fraught with many 
confusing and contradictory results. The purpose of the 
current quantitative review was to identify the study 
characteristics that have contributed to the trend towards 
null findings. Three study characteristics--high risk study 
design, use of self-report measures and use of fatal MI as a 
disease criterion--were found to be associated with null 
findings. The current research documented that the 
increased use of these types of studies in recent years has 
contributed to the trend towards null findings. 
In addition, the current review found several results 
that converge to suggest that DBS bias has produced the null 
findings in high risk studies. First, the percentage of 
Type A's was high in both the diseased comparison and 
diseased groups. Second, the prevalence of TAB in patients 
with CHO was significantly higher than found in healthy 
populations. Finally, range restriction formulas accurately 
estimated the actual correlations found in recurrent CHO 
studies. 
Other subject selection biases do not appear to offer a 
plausible alternative explanation for the higher percentages 
of Type A's found among subjects with CHO. One would 
suspect that the percentage of Type A's found in the study 
sample would vary with the way subjects were selected into 
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the study if other subject selection biases influence this 
area of research. However, the correlation between TAB and 
CHO was consistent across studies that selected subjects 
using a variety of methods. Therefore, the results of the 
current research suggest that the magnitude of the 
correlation between TAB and CHO is not greatly influenced by 
the methods used to recruit subjects with the exception of 
the high risk versus healthy comparison group distinction. 
Reasons for the Trend Towards Null Findings 
Increased use of recurrent CHO studies. Recurrent CHO 
studies have only recently become popular; in the early 
1970's, researchers reasoned that recurrent CHO studies were 
more cost effective than healthy population prospective 
studies. They arrived at this conclusion because they 
believed that recurrent CHO studies with higher base rates 
of disease permitted smaller sample sizes (e.g., Sondik, 
Brown & Silvers, 1974; The Multiple Risk Factor Intervention 
Trial; MRFIT group, 1977) than healthy population studies. 
These researchers reasoned that smaller sample sizes could 
be used in recurrent CHO studies because higher base rates 
increase the statistical power of a study. Unfortunately, 
these researchers failed to recognize that recurrent CHO 
studies increase the base rate at the cost of greater range 
restriction. The results of the current research strongly 
suggest that increasing the base rate by using high risk 
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subjects is by no means a cost-effective or methodologically 
sound strategy for research on CHO. 
Increase in extent of CAD in angiography patients. A 
number of recent angiography studies have failed to find a 
relationship between TAB and CAD. Miller et al. (1988) 
suggested one possible explanation. As expertise has 
increased in screening procedures for selecting patients for 
diagnostic angiography, the likelihood has decreased for a 
healthy person to be scheduled for an angiography. 
Therefore, recent angiography studies have not selected 
healthy subjects for study and so DBS bias has attenuated 
the correlation between TAB and CHO in recent years. In 
support of this hypothesis, the correlation between CAD and 
the traditional risk factors (Fried & Pearson, 1987), and 
CAD and TAB (Miller et al., 1988 and the current review) has 
decreased in recent years. In addition, the percentage of 
Type A's in recent studies has been similar to that found in 
patients with CHO. 
Increased use of self-report measures. Since the 
National Heart, Blood and Lung Institute (1978) declared 
that TAB was a risk factor for CHO, many CHO researchers 
began to use indicators of TAB in their studies. Perhaps in 
an effort to reduce costs and save time, self-report 
measures have been favored over the SI. Unfortunately, 
self-report measures of TAB have a low correlation with CHO. 
Thus, many studies have found null results and the trend 
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towards using self-report measures has contributed to the 
trend towards null findings. 
The use of fatal MI as a disease criterion. In recent 
years, the use of fatal MI as a disease criterion has always 
led to null results. There are a number of potential 
explanations for these findings. For example, some 
researchers (e.g., Correspondence. 1988) have criticized the 
reliability of death certificate information used as an 
indicator of fatal MI in many studies. Thus, the 
reliability of the disease criterion is one potential 
explanation for the null findings. 
Two other possible explanations are worth mentioning. 
Perhaps TAB may be less predictive of fatal MI because fatal 
MI occurs most frequently in older subjects whose TAB status 
has been altered by lifestyle changes accompanying 
retirement or a prior history of MI (age bias). Second, 
there are two types of fatal MI's: sudden death and 
nonsudden death. Perhaps TAB is only predictive of one of 
these types of fatal MI (Brackett & Powell, 1988). 
The MRFIT Study. The results of the MRFIT (Shekelle, 
Hulley et al., 1985) are important to consider because the 
MRFIT has been claimed by many to be the largest and most 
sophisticated study to examine the relationship between TAB 
and CHO in recent years. MRFIT selected subjects on the 
basis of their traditional risk factor status. The 
percentage of Type A's among individuals who remained 
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healthy throughout the MRFIT was higher than any of the 
healthy population studies and very similar to that found in 
patients with a prior history of CHO. 
One possible explanation for the higher percentage of 
Type A's in the MRFIT study is that TAB is positively 
correlated with the traditional risk factors that were used 
to select subjects for the MRFIT. Although previous 
research suggests there is no simple linear relationship 
between TAB and the traditional risk factors (see Booth-
Kewley & Friedman, 1987), a nonlinear or multivariate 
relationship may exist. 
The findings of the Belgian Heart Disease Prevention 
Project (Kittel, 1986) are also supportive of this 
hypothesis. This study was a successful intervention 
designed to prevent CHO by reducing individuals' levels of 
risk on the traditional risk factors. This study found a 
strong relationship between TAB and CHO in the control group 
and no relationship in the treatment group after treatment. 
Thus, the intervention appears to have altered the 
relationship between TAB and CHO in some unknown way. In 
addition, only one other study that selected subjects on the 
basis of their risk factor status (Belmaker, Pollin, Jenkins 
& Brensike, 1976) found significantly more Type A's in the 
diseased comparison group. 
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Suggestions for Future Research 
Healthy population studies are required to obtain 
accurate estimates of the percentage of Type A's found in 
healthy samples stratified by the other risk factors for 
CHD. Although healthy population estimates are available 
for the SI, only one study (Moss et al., 1986) has used 
representative sampling techniques. Such studies are 
required to assess the magnitude of the relation between TAB 
and CHD, and TAB and the traditional risk factors. 
Future healthy population prospective studies that 
assess TAB by the SI would be useful for validating the 
results of the WCGS. At present, only three prospective 
studies have assessed TAB by the SI. 
Future research to control for and confirm that DBS 
bias is a problem in high risk studies requires researchers 
to use continuous indicators of disease severity and TAB 
(Knaus et al., 1984; Miller et al., 1988). By using 
continuous indicators, researchers can demonstrate how the 
relation between TAB and CHD is influenced by limiting the 
range of CHD to only individuals with severe disease (e.g., 
Fried & Pearson, 1987). 
There are other advantages to using continuous 
measures. categorization reduces associations between 
variables. Thus, the association between TAB and CHD is 
underestimated when dichotomous variables are used. The 
artifactual categorization of TAB and CHD is also a problem 
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because optimal categorization can vary from study to study 
(Rorer et al., 1966). Therefore, categorization leads to 
arbitrary changes in the magnitude of the association 
between TAB and CHD across different studies. The 
development and use of continuous measures of TAB (e.g., 
Friedman et al., 1986; Knaus et al., 1984) is an important 
area for future research. 
Another measurement issue is the development of self-
report measures of TAB. The current research suggests that 
self-report measures of TAB are not highly correlated with 
CHD. The development of more valid self-report measures of 
TAB to is another area for future research. 
The presence of age and sex bias could not be 
adequately tested in the current research because most 
previous research has been conducted on middle aged men. To 
understand how the relationship between TAB and CHD is 
influenced by age and sex requires studies that examine 
women and individuals at different ages. 
Finally, future research is required to understand why 
there appears to be a relationship between TAB and CHO. One 
possibly suggested by the current research is that TAB may 
be more closely associated with the traditional risk factors 
than has been suspected. Another question is why TAB does 
not appear to be predictive of fatal MI. 
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POTENTIAL APPLICATIONS OF THE OT MODEL TO FUTURE RESEARCH 
The DT model can be used to define other biases that 
may influence the relationship between TAB and CHO. The 
following section of this dissertation describes how the DT 
model can be used to define another type of spectrum bias 
referred to as mortality bias. In addition, this section 
discusses suggestions for how the DT model can be applied to 
future research on TAB and CHO. 
Mortality Bias in Cross-Sectional High Risk Studies 
Mortality bias reduces the degree of statistical 
association between TAB and CHO in a similar manner to DBS 
bias. For DBS bias, healthy observations are excluded from 
the study sample and this reduces the specificity. 
Mortality bias occurs when the sensitivity is reduced by 
patient mortality (Miller et al., 1988). Similar to the 
reduction in specificity produced by DBS bias, the decrease 
in sensitivity produced by mortality bias attenuates risk 
ratios. 
Figure l(c) can be used to illustrate how mortality 
bias reduces the sensitivity. The line labeled Q'' in 
Figure l(c) is an exclusion point and indicates where 
patients' CHO is sufficiently severe that a fatal MI has 
occurred. In Figure l(c), more Type A's are located in the 
section of the distribution where fatal MI's occur. The 
exclusion of subjects with fatal MI decreases the 
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sensitivity because more Type A's incur a fatal MI than Type 
B's in the extreme diseased end of the continuum (see Figure 
l(c)). This loss of Type A's to mortality decreases the 
percentage of Type A's in the diseased group in the study 
sample. The sensitivity decreases as the number of 
individuals who have incurred a fatal MI before the 
beginning of the study increases. 
Typically, mortality bias is not as great a problem as 
DBS ·bias because fewer subjects incur fatal disease than 
remain healthy. For example, 96% of the subjects did not 
incur an initial MI and so were excluded from the recurrent 
CHD study in the first 8.5 years of the WCGS study. In 
contrast, the percentage of fatal MI's in the WCGS that 
would not be included in future follow-up studies was only 
1%. That is, only 1% of the sample was excluded that could 
produce mortality bias. The percentage of fatal MI's in the 
22 year follow-up period was not substantially greater--only 
7% (Ragland & Brand, 1988b). Recurrent CHD studies exclude 
all subjects who have not incurred an MI. Therefore, the 
spectrum of disease in these studies is limited to only the 
most severely diseased subjects. In comparison to mortality 
bias, a substantially higher percentage of subjects are 
excluded from studies that produce DBS bias. Therefore, 
mortality bias is typically not as great a problem as DBS 
bias. Yet, many researchers have argued that mortality bias 
may have influenced their results while the possibility of 
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DBS bias has been ignored (Feinstein, 1986; Ransohoff & 
Feinstein, 1978). 
Implications of the DT Model for Future Research 
Research to determine what biases are important. 
Methodological concerns have been dominated by a concern 
with selection biases (Sackett, 1979). For example, 
researchers have consistently suggested that contradictory 
findings in research on TAB and CHO have been produced by 
problems associated with selection biases (Matthews, 1988). 
One purpose of the current paper is to suggest that spectrum 
biases also deserve consideration. 
Quantitative reviews (e.g., Miller et al., 1988) can 
be used to determine the impact of various biases within a 
research domain (Einarson, Leeder, & Koren, 1988). These 
reviews can be used to determine which biases have a great 
influence on the magnitude of the correlation between TAB 
and CHD and which biases may not be important. 
Interpretation of results. Quantitative reviews can be 
useful for determining the relative importance of risk 
factors. These are many well known reasons why a researcher 
may not find an association between a risk factor and a 
disease (e.g., inadequate statistical power, unreliability 
in measurement). Spectrum and selection biases are 
potential explanations for null findings that should be 
carefully considered before researchers are certain there is 
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no substantial association between a risk factor and a 
disease. 
Detecting mortality bias. Researchers have not tested 
the extent to which mortality bias may have influenced the 
magnitude of the relationship between TAB and CHO. One 
could determine the extent to which mortality bias is a 
problem by testing whether the sensitivity between TAB and 
CHO decreases in populations in which a higher percentage of 
individuals have incurred a fatal MI. That is, researchers 
should compare the sensitivities across different subgroups 
of individuals or individuals in different studies with 
varying mortality rates (Ransohoff & Feinstein, 1978). One 
would have evidence of mortality bias if the sensitivities 
decrease in samples with higher mortality rates. 
Investigating other types of spectrum biases. This 
dissertation only discussed two types of spectrum biases 
that may contribute to confusing and contradictory findings 
in epidemiological research--DBS bias and mortality bias. 
The DT model can be used to describe other types of spectrum 
biases. Similarly, there is no reason to consider only 
cases where the spectrum of disease is reduced. Spectrum 
biases may be concerned with any aspect of the pathology, 
clinical features or co-morbidity of the study sample 
(Ransohoff & Feinstein, 1978). 
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Research to assess the prevalence of risk factors. 
Establishing healthy population estimates of the specificity 
of a risk factor for different populations is an important 
aspect of research because healthy population estimates are 
useful for ascertaining the true magnitude of the 
association between a risk factor and a disease across the 
entire spectrum of the disease. 
Planning sample sizes for future research. Researchers 
who aspire to conduct high risk studies should attempt to 
estimate a priori the extent to which DBS bias attenuates 
risk ratios in their high risk studies. Appendix B of this 
manuscript presents a derivation of a formula that can be 
used for calculating the expected reduction in the RR and/or 
the odds ratio for a high risk studies. Researchers should 
use this formula to calculate expected risk ratios and to 
estimate the sample size required to obtain a statistically 
significant result in high risk studies. 
The expected power analyses may be quite discouraging 
to those interested in conducting high risk studies. In 
many cases, the estimated reduction in risk can be 
substantial. For example, 2.3% of all subjects in the WCGS 
at the 4.5 year follow-up were found to have a symptomatic 
MI, and the RR reported in the healthy population 
prospective study was 2.5 (see Table 2). Among those 
subjects who incurred an initial MI, 16% incurred a 
recurrent CHD. Applying these estimates to the formulas 
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presented in Appendix B, the estimated RR is 1.2 for the 
WCGS recurrent CHO results. This result is quite similar to 
the actual results (RR= 1.1) of the recurrent CHO of the 
WCGS. 
The difference between the healthy population findings 
and the high risk study findings is substantial; varying 
from 2.5 to 1.1. This difference is almost entirely 
predicted by a formula that estimates the degree to which 
DBS bias reduces statistical associations in high risk 
studies. The research reported in the results section of 
this dissertation found that similar DBS bias formulas for 
~·s predicted the small associations between TAB and CHO 
reported in other recurrent CHO studies. All of these 
findings suggest that DBS bias is a serious problem in 
research on TAB and CHO. DBS bias may also be a problem in 
other research domains. 
One can estimate the sample sizes for the healthy 
population and high risk studies by calculating the minimum 
sample size required to obtain a chi-squared value that 
would be significant at some level of significance (e.g., R 
< .05). These power analyses are useful for understanding 
how much of an increase in sample size is required to obtain 
a statistically significant result in high risk studies. 
The estimated sample size required to obtain a statistically 
significant result from the recurrent CHO study using an 
estimated RR of 1.2 is 2,378. In comparison, the minimum 
77 
required sample size to obtain a statistically significant 
result in the healthy population study that reported a RR of 
2.s would be 1,092. These results suggest much larger 
sample sizes may be required for research conducted in 
recurrent CHO populations than for heathy population 
studies. These findings are consistent with the research 
presented in the results section of this dissertation. 
These results suggested that DBS attenuates correlations in 
recurrent CHO studies. 
Another possibility before conducting new studies that 
researchers should consider is to estimate the influence of 
DBS bias in previous high risk studies. For example, biased 
specificities for TAB found in high risk studies could have 
been replaced with a healthy population estimate of the 
specificity and new adjusted odds ratios can be estimated 
(Miller et al., 1988). The healthy population estimate of 
the specificity can be obtained by a review of the 
literature of healthy population studies such as the one 
conducted in this dissertation. The difference between the 
actual and adjusted odds ratio can be used as an indicator 
of the extent to which DBS bias has attenuated associations 
between TAB and CHO in previous high risk studies7 • 
Using previous research from other sciences. Although 
the concept of spectrum bias has only recently been 
discussed in epidemiology (Feinstein, 1986; Miller et al., 
1988; Philbrick, Horwitz, Feinstein, Langou & Chandler, 
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1982; Ransohoff & Feinstein, 1978), spectrum bias has a long 
history in other scientific endeavors. There are several 
relevant areas of research the interested reader may 
consult. In industrial psychology (Lord & Novick, 1968; 
Thorndike, 1949) and statistics (Little & Rubin, 1987; 
Rydberg, 1963), spectrum biases have been referred to as 
range restriction. In economics, the term sample selection 
bias has been used (Heckman, 1979). 
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APPENDIX B 
ESTIMATING REDUCTION IN RISK 
This appendix illustrates a technique for estimating 
the reduction in risk produced by DBS bias in a high risk 
study from the results of healthy population studies. All 
one requires are values for the statistical parameters that 
describe the. DT model presented in Figure l(b). These 
parameters are (a) the probability of possessing the risk 
factor (e.g., being a Type A) in the study sample (b) the 
magnitude of the g', (c) the location of Q and Q', and (d) 
the shape of the distributions of the risk factors. For the 
equations presented in the current paper, the shape of the 
frequency distributions for different values of the risk 
factor are assumed to be normal and symmetric with respect 
to disease status. 
To illustrate the estimation procedure, an example from 
research on TAB and CHO is used. The RR associated with 
recurrent CHO is obtained from an estimate of the 
probability of incurring a MI in a healthy individual 
(p(d)). The probability of recurrent CHO in the future for 
a healthy individual (the probability of recurrent disease 
in a healthy individual= p(rdh)) is described by the 
following equation 
p(rdh) = p(d)p(rd) (1) 
where p(rd) equals the probability of recurrent CHO in 
a sample of individuals with a history of MI. In some 
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cases, an estimate of p(rdh) may be obtained directly from 
the results of a healthy population prospective study. In 
other cases, estimates of p(rd} and (d} can be obtained from 
prior research and these values can be used to calculate 
p(rdh). 
The next step is to obtain ~ scores that satisfy the 
following equations. 
zAh - Zeh = g I 
w1p (rdAh} + w2p (rd8h} = p (rdh} 
(2) 
( 3) 
where "zh" equals the z score associated with p(rdh), the A 
and B subscripts indicate Type A and Type B behavior and "w" 
indicates the weights associated with the probability of 
being Type A or Type B in the healthy population study 
sample. The 'A' and 'B' subscripts for the A and B 
distributions indicate which distribution--Type A or B--the 
z score or probability is estimated from. For example, 
p(rdAh) indicates the probability of recurrent CHD in 
healthy Type A's. Equation (2) is the standard equation for 
the effect size g' (Glass, McGraw, & Smith, 1981). Equation 
(3) indicates that the sum of the number of Type A's and B's 
who develop recurrent CHD equals p(rdh). 
The simplest way to calculate the zh scores is to use a 
standard ~ score conversion table. One simply finds the 
pair of zh scores with probability values that sum to p(rdh) 
and that satisfy equation (2). The zh scores can be used to 
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estimate the RR. The formula for the RR is 
p ( zAh) p ( Ze) /p ( ZA) p (Zeh) (4) 
where each .P(Z_) equals the probability value 
associated with a z score, and a z without a "h" sign equals 
the z score associated with the probability that a healthy 
individual will incur a MI. The formula for the odds ratio 
is 
(p(ZA)-p(zAh)) (p(rdeh)/(p(Ze)-p(zeh)) (ZAh)) (5) 
Furthermore, 
p ( zAh) / (p (Zeh) + p ( zAh) ) 
equals the sensitivity and 
(p ( Ze) -p (Zeh))/ (p ( Ze) 
equals the specificity. 
(6) 
(7) 
The following is an example of how one can use the 
preceding equations to estimate the RR between TAB and CHO 
in the recurrent CHO of the WCGS from the healthy population 
results. In order to estimate the RR, one first obtains an 
estimate of p(rd). For example, the WCGS reported that 
approximately 2.3% of the subjects developed symptomatic 
MI's over the 4.5 year follow-up period. Thus, p(rd) equals 
2.3%. 
Second, one obtains the ~ scores associated with the 
percentage of Type A's and B's who develop CHO from the 
healthy population results. The ~ scores associated with 
the percentages of Type A's and B's that incur a MI can be 
obtained from a standard score conversion table. These z 
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scores would both be located at£ in Figure l(b). One~ 
score is associated with the Type B distribution and one ~ 
score is associated with the Type A distribution. 
Subtracting the Type B ~ score from the Type A ~ score 
provides an estimate of g'. For example, the~ score 
associated with the percentage of Type A's that incurred a 
MI in the WCGS is 1.85. The ~ score is 2.22 for the 
percentage of Type B's. The difference between the Type A 
and B ~ scores is 0.37. Therefore, the g' for the WCGS is 
0.37. 
The next step is to obtain~ scores for£'. For 
recurrent CHO studies, g' is the point at which individuals 
develop recurrent CHO. To obtain these estimates, one only 
requires an estimate of p(rd'). In the case of the WCGS, 
the recurrent CHO rate was 16%. Using equations 2 and 3, 
the estimated result for the recurrent CHO study is 1.2. 
Table 2 presents the results for the actual and 
estimated recurrent CHO study of the WCGS. In no cases are 
the estimated results significantly different from actual 
results. The only discrepancy between the estimated and 
actual results occurs in the sensitivity (this also accounts 
for the lower g'). For a discussion of possible reasons why 
the sensitivity in high risk studies is lower than the 
estimates, see the section of the current paper entitled age 
bias. 
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The range restriction formulas derived in the current 
paper are based on the assumption that the Type A and B 
distributions are symmetric with respect to CHO status and 
that the relationship between TAB and CHO is linear. In 
many cases, this may be an unreasonable assumption. The 
need for range restriction formulas based on less 
restrictive distributional assumptions is area of future 
research. Research using quasi-continuous measures of TAB 
and CHO would be useful to determine that the relationship 
between TAB and CHO is linear and bivariate normal. 
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Endnotes 
1. Most research has treated CHO as a dichotomous variable 
(e.g., MI versus no MI, angina versus no angina). The 
current research defines CHO as a continuum in which MI or 
angina are discrete points along a spectrum of disease 
severity. Many researchers (e.g., Knaus, Wagner & Draper, 
1984; Miller, Turner, Tindale & Posavac, 1988) have noted 
that defining CHO as a continuous variable is a useful way 
of conceptualizing CHO. When CHO is conceptualized as 
occurring along a continuum, one can describe high risk 
studies as a sample in which only individuals from the 
diseased range of CHO are selected for study. 
2. Previous research suggests the relationship between TAB 
and CHO is linear (Booth-Kewley and Friedman, 1987) and that 
the distributions of Type A's and B's are normally 
distributed (Kittel et al., 1978). However, the 
distribution of TAB with respect to CHO status remains 
unknown because researchers have relied on statistical 
analyses that treated CHO and TAB as dichotomous variables. 
3. Hedges and Olkin (1985) have recommended correcting ~·s 
for unreliability to obtain a more accurate estimate of the 
theoretical relation between the variables of interest. 
Previous research (Booth-Kewley & Friedman, 1987) has 
addressed this question. Correction for unreliability was 
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not undertaken in the current research because the focus was 
to identify study characteristics that are associated with 
positive and null findings. 
A chi-squared test (see Hedges & Olkin, 1985) was used 
to determine if the amount of inter-study variance not 
attributable to sampling variability as indicated by the IVI 
was statistically significant. The chi-squared test was 
almost always significant. This finding is not surprising 
considering the large sizes examined in the current 
research. However, the magnitude of the IVI in most cases 
suggests that the actual percentage of variance attributable 
to inter-study variation is quite small. Therefore, the 
results of the chi-squared tests are not reported. 
4. The range restriction formula that is presented in 
Alexander et al. (1985) is 
E(r) = 
_, 1/2 
~I 
Where E(r) equals the expected value of ~, rxy is the 
value or r observed in the healthy population study, and X 
and Y are equal to 
X = 1 - (h2/phi2) + (h/phi) (Zxc> 
Y = 1 - (r2xy) (h2/phi2) + r 2xy) (h/phi) (Zxc> 
Where phi is the selection ratio, h is the height of 
the normal curve on X corresponding to the observed phi, and 
Zxc is the standard score cutoff point on X for phi. 
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5. The substantial inter-study variation (IVI = .132) in 
the case control studies that assessed TAB by the SI was 
produced entirely by one study (Wielgosz et al., 1988; ~ = -
.04). The WMR for case-control studies that assessed TAB by 
the SI excluding this study (WMR = .41, N =505; IVI = .009) 
is much higher and consistent with the results for case 
control studies using self-report measures of TAB (see Table 
2) • 
The large WMR's associated with case control studies 
are inconsistent with the results of other more 
methodologically rigorous designs. This finding is 
consistent with other meta-analyses (Einarson, Leeder & 
Koren, 1988). Therefore, the results of case-control 
studies should probably be treated with more caution than 
other type of designs. 
6. Another frequently mentioned explanation for the null 
findings in high risk studies has been that a person's TAB 
status may change after incurring CHD. However, this 
hypothesis appears to be incorrect because the prevalence of 
TAB in subjects with CHD is similar in both prospective and 
cross-sectional studies. 
For the studies reported in the current review, 
subjects' TAB status was assessed soon after the coronary 
event. Therefore, TAB status may change after the first few 
months following a MI. 
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7. Unfortunately, replacing healthy population estimates of 
the sensitivity or specificity to correct for biased 
estimates may frequently be impractical. One reason is that 
healthy population estimates of individuals with similar 
characteristics to the diseased sample are often 
unavailable. Furthermore, all the characteristics that may 
be important are often unknown. Thus, the omitted variable 
problem may produce misleading results when adjusted risk 
ratios are used. 
Another problem with replacing a study sample estimate 
with a healthy population estimate is that this reduces the 
study design to essentially a case-control design even if 
the original design was prospective. 
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